IIIB期（T4 N2）；IIIC期（T4 N3）；IVA期（M1a）胸腔积液或心包积液（NSCL-14）

评估和治疗：IIIB期（T4 N2）；IIIC期（T4 N3）；IVA期（M1a）胸腔积液或心包积液（NSCL-14）

• IIB期（T3侵犯、N0）和IIIA期（T3侵犯、N1；T4侵犯/大小、N0-1）（NSCL-5，6，7）
  

• IVA期（M1b）和IVB期（M1c）（孤立性或局限性转移的根治性治疗）（NSCL-15，16）
• 根治性治疗完成后的监测（NSCL-17）
• 复发和转移的治疗（局部治疗与症状控制）（NSCL-18）
  

• 晚期或转移性疾病全身治疗前评价和生物标志物检测（NSCL-19, 20）
  

l FDG-PET/CT performed skull base to mid-thigh. Positive FDG-PET/CT scan findings for mediastinal nodal or distant disease need pathologic or other radiologic confirmation. If FDG-PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation.
o 放射治疗原则（NSCL-C） .
s If MRI is not possible, CT of head with contrast.
w 同步放化疗方案（NSCL-F）.
z For patients who have received sequential chemoradiation, durvalumab can be considered as consolidation immunotherapy or, if EGFR exon 19 deletion or L858R mutation, osimertinib is recommended.
ii Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and fluid is non-bloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor.

---

NCCN-NSCLC-2026V6   

---

NCCN非小细胞肺癌指南导航